NDAORALSUSPENSIONPriority Review
Approved
May 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
4/8 — Partial
Priority Review
PROGLYCEM (diazoxide) by Teva is clinical pharmacology diazoxide produces a dose-related increase in blood glucose, due primarily to an inhibition of insulin release from the pancreas, and also to an extrapancreatic effect. First approved in 1976.
Drug data last refreshed 5h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PROGLYCEM (diazoxide) is an oral suspension that raises blood glucose by inhibiting insulin release from the pancreas and producing extrapancreatic hyperglycemic effects. It is used to manage severe hypoglycemia in patients where other treatments are inadequate or contraindicated. The drug's hyperglycemic effect begins within one hour and typically lasts no more than eight hours with normal renal function.
LOE Approaching
A niche, specialty indication product with modest team scale (3 linked jobs) facing imminent loss of exclusivity.
Mechanism of Action
CLINICAL PHARMACOLOGY Diazoxide produces a dose-related increase in blood glucose, due primarily to an inhibition of insulin release from the pancreas, and also to an extrapancreatic effect. The hyperglycemic effect of diazoxide begins within an hour and generally lasts no more than eight hours in…
Indications
Worked on PROGLYCEM at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.